Medtronic (NYSE:MDT) Earns “Overweight” Rating from Barclays

Medtronic (NYSE:MDT)‘s stock had its “overweight” rating restated by investment analysts at Barclays in a note issued to investors on Friday,Benzinga reports. They presently have a $116.00 price objective on the medical technology company’s stock. Barclays‘s price target would indicate a potential upside of 14.86% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Jefferies Financial Group restated a “hold” rating and issued a $110.00 price target on shares of Medtronic in a research note on Wednesday, November 19th. UBS Group restated a “neutral” rating and issued a $104.00 target price on shares of Medtronic in a research report on Wednesday, February 4th. JPMorgan Chase & Co. lifted their target price on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. CICC Research initiated coverage on Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating for the company. Finally, Citigroup initiated coverage on shares of Medtronic in a research note on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price objective on the stock. Sixteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $111.21.

Medtronic Stock Performance

MDT stock traded up $0.11 during mid-day trading on Friday, reaching $100.99. The company had a trading volume of 2,048,727 shares, compared to its average volume of 8,159,982. Medtronic has a one year low of $79.55 and a one year high of $106.33. The stock has a market capitalization of $129.47 billion, a P/E ratio of 27.24, a P/E/G ratio of 2.66 and a beta of 0.71. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The stock’s 50-day simple moving average is $99.32 and its two-hundred day simple moving average is $96.35.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts anticipate that Medtronic will post 5.46 EPS for the current year.

Institutional Investors Weigh In On Medtronic

A number of institutional investors and hedge funds have recently modified their holdings of MDT. Corundum Trust Company INC acquired a new position in Medtronic in the 3rd quarter valued at approximately $27,000. Lodestone Wealth Management LLC purchased a new position in shares of Medtronic during the 4th quarter valued at $27,000. Anfield Capital Management LLC increased its stake in shares of Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the last quarter. Board of the Pension Protection Fund acquired a new stake in Medtronic during the fourth quarter valued at $29,000. Finally, GoalVest Advisory LLC purchased a new position in Medtronic in the fourth quarter valued at about $29,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).